UNIMED HITS ENROLLMENT TARGET FOR MARINOL PHASE III STUDIES IN AIDS PATIENTS
UNIMED HITS ENROLLMENT TARGET FOR MARINOL
PHASE III STUDIES IN AIDS PATIENTS
SOMERVILLE, N.J., Jan. 8 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that it has reached its enrollment target for its Phase III studies of Marinol(R) (dronabinol) for appetite stimulation and prevention of weight loss in AIDS patients.
"With the achievement of our enrollment objectives, we are on schedule for completion of this study and filing of a Supplemental New Drug Application (SNDA) by our target date of July 1992," said Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer.
Marinol is currently marketed as an antinausea pharmaceutical for the treatment of cancer chemotherapy patients. Phase III multicenter studies for appetite stimulation and prevention of weight loss in AIDS patients are being conducted in a number of cities around the United States. Marinol has been granted Orphan Drug designation for this use. Approval of Marinol for this use in AIDS patients and, ultimately, in cancer patients will expand the market in which Marinol competes to over $1 billion worldwide.
UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients. The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
/CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
(UMED) CO: UNIMED, Inc. ST: New Jersey IN: MTC SU: PS -- NY050 -- 7625 01/08/92 09:15 EST